Arie Perry, MD

Neuropathologist

Dr. Arie Perry, director of Neuropathology at UCSF Medical Center, specializes in brain tumor pathology and genetics. He also maintains an international consult service for challenging cases involving brain tumor diagnosis. His research focuses on biomarker development for enhanced diagnosis, prognostic accuracy and management of brain tumor patients.

Perry received a medical degree and pathology residency training at the University of Texas, Southwestern in Dallas, followed by fellowships in surgical pathology and neuropathology at the Mayo Clinic in Rochester, Minn. He is a member of several professional organizations, including the American Association of Neuropathologists, International Society of Neuropathology, U.S. and Canadian Association of Pathology and the Society for Neuro-Oncology. He is the recipient of numerous teaching awards and has authored various publications, including the textbook, "Practical Surgical Neuropathology." He is a professor of pathology and neurosurgery at UCSF and director of the Neuropathology Fellowship Training Program.

Conditions & Treatments

Academic Title

Professor

More about Arie Perry

Education

University of Texas Southwestern Medical School 1990

Residencies

University of Texas Hospital, Dallas, Pathology 1994

Fellowships

Mayo Clinic, Rochester, Minn., Surgical Pathology, Neuropathology 1998

Selected Research and Publications

  1. Pekmezci M, Villanueva-Meyer JE, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Chamyan G, Maher OM, Khatib Z, Kleinschmidt-DeMasters BK, Samuel D, Mueller S, Banerjee A, Clarke JL, Cooney T, Torkildson J, Gupta N, Theodosopoulos P, Chang EF, Berger M, Bollen AW, Perry A, Tihan T, Solomon DA. The genetic landscape of ganglioglioma. Acta Neuropathol Commun. 2018 Jun 07; 6(1):47.
  2. Luks TL, McKnight TR, Jalbert LE, Williams A, Neill E, Lobo KA, Persson AI, Perry A, Phillips JJ, Molinaro AM, Chang SM, Nelson SJ. Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas. Transl Oncol. 2018 Jun 05; 11(4):941-949.
  3. López GY, Perry A, Harding B, Li M, Santi M. CDKN2A/B Loss is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma. Neuropathol Appl Neurobiol. 2018 May 27.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.